Effect of Ensifentrine on Sputum Markers of Inflammation in COPD

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This is a randomized, double-blind, placebo-controlled, two-period cross-over study of nebulized ensifentrine (3 mg) or placebo administered BID for two 8-week Treatment Periods. All participants with receive both ensifentrine and placebo during participation. There are 7 in-clinic visits over a total duration of up to 24 weeks participation.
Epistemonikos ID: 76b6072fcd249e1972124289b2a5f849190dcd24
First added on: May 10, 2024